Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Nuvation Bio Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 351.12M shares outstanding
USNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6.
It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer.
The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Leadership
Colleen Sjogren
Chief Commercial Officer
David Hung, M.D.
President, Chief Executive Officer and Director
David Liu, M.D., Ph.D.
Chief Medical Officer
Moses Makunje, CPA
VP Finance, Principal Accounting Officer
Employees
273
Country
US
Sector
Healthcare
Website
nuvationbio.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Option Exercise | 100.0K | $187.0K | Aug 19, 2026 |
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Option Exercise | 100.0K | -- | Aug 19, 2026 |
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Sale | 100.0K | $709.2K | Aug 19, 2026 |
 Sauvage Philippe | Chief Financial Officer | Option Exercise | 40.0K | $86.8K | Jul 15, 2026 |
| Sauvage Philippe | Chief Financial Officer | Option Exercise | 1 | -- | Jul 15, 2026 |
| Sauvage Philippe | Chief Financial Officer | Option Exercise | 40.0K | -- | Jul 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
David Hung, M.D. 2. · superseded by Form 4· filed Mar 2024 | 6.1B | n/a | 13D |
 Hung David PRESIDENT AND CEO, Director, 10% Owner | 59.3M | 16.9% | FORM 4 |
FMR LLC | 52.2M | 14.9% | 13F |
FMR LLC · also on 13F· may incl. warrants· filed May 2025 | 50.6M | 14.4% | 13G |
BlackRock, Inc. | 27.6M | 7.9% | 13F |
Decheng Capital LLC | 26.0M | 7.4% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2025 | 21.7M | 6.2% | 13G |
Omega Fund V, L.P. 2. · may incl. warrants· reaffirmed 13F Aug 2026 | 13.1M | 3.7% | 13D |
VANGUARD CAPITAL MANAGEMENT LLC | 11.9M | 3.4% | 13F |
Omega Fund Management, LLC | 8.1M | 2.3% | 13F |
Insiders
- Hattersley GaryCHIEF SCIENTIFIC OFFICER
- Sauvage PhilippeChief Financial Officer
- Wentworth KerryCHIEF REGULATORY OFFICER
- Markel StacyCHIEF PEOPLE OFFICER
- Mashal RobertDirector
- FALBERG KATHRYN EDirector
- BLICKENSTAFF KIM DDirector
- Cui XiangminDirector
- Bazemore Robert BDirector
- VERNON W ANTHONYDirector
based on 351.12M shares outstanding
US30d Avg
5.71M
60d Avg
5.16M
90d Avg
5.39M